Anti CD30 CAR T Cell Therapy (First Song Therapeutics)

N/A

Report date: 2024/11/25 20:00:28

Base Information

Drug NameAnti CD30 CAR T Cell Therapy (First Song Therapeutics)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 modulators

TargetsTumor necrosis factor receptor superfamily member 8

Therapy Area/IndicationsAngioimmunoblastic T-cell LymphomaLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, Anaplastic +[7]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaPending

Originator CompaniesZhejiang University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesZhejiang University

Active IndicationsN/A

Inactive IndicationsAngioimmunoblastic T-cell LymphomaLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, Anaplastic +[7]

Other Information

ATC CodeN/A